In a different strategy to approach cancer treatment using GM-CSF, investigators designed talimogene laherparepvec (T-VEC), an oncolytic herpes virus engineered to express GM-CSF, which was approved by the U.S. FDA in 2015 for use in recurrent metastatic melanoma [51]. The gene discussed is CSF2; the disease is metastatic melanoma.